Accueil / Communiqués / Nucelis Partners with Darwin to Build Business in China; Signs First Development Agreement

Nucelis Partners with Darwin to Build Business in China; Signs First Development Agreement

Monday, December 10th 2018 at 1:30pm UTC

SAN DIEGO–(BUSINESS WIRE)– Nucelis, the microbial strain development subsidiary of agriculture
biotech company, Cibus, today announced a partnership agreement with
Nanjing Darwingenetech Co, Ltd (Darwin) to jointly identify and enter
into agreements with China based customers for Nucelis’ proprietary
gene-editing and advanced fermentation expertise to improve fermentation
yields and reduce costs.

In collaboration with this partnership with Darwin, Nucelis also
finalized the signing of its first customer agreement. Financial terms
of the agreement were not disclosed.

“We are pleased to be business development partners with Nucelis and to
have signed our first customer agreement,” said Jim Xu, President of
Darwin and Chairman of Jiangsu Zenji Pharmaceuticals Ltd.

Jack He, Senior Manager of Darwin, added: “Nucelis has a very valuable
and differentiated portfolio of technology and services to assist
Chinese manufacturers of food ingredients, animal feed, and other
products made via fermentation.”

“We are delighted to partner with Darwin as we build our business in
China, where we see a large and growing opportunity in the world’s
largest market for products made using fermentation,” said Sean
O’Connor, Ph.D., President and CEO of Nucelis. “Our innovative and
proprietary strain development and fermentation expertise are an ideal
fit for potential customers in the region, as evidenced by the signing
of our first customer agreement.”

Nucelis is a wholly owned subsidiary of Cibus, a biotechnology company
with advanced technologies to precisely target and direct a plant’s
natural gene-editing processes. The Nucelis Accelerated Strain
Advancement Platform (ASAP™) is a specialty ingredient development
platform that combines the precision of the Cibus suite of gene-editing
technologies, the Rapid Trait Development System (RTDS™),
with advanced fermentation and pilot scale facilities and experience,
and proprietary downstream, and purification processes. This approach
enables Nucelis to efficiently develop and deliver high-value,
performance-focused, non-transgenic specialty ingredients for partners
in the nutrition, personal care, flavor and fragrance markets, and for
future applications in Ag biologicals, active pharmaceutical ingredients
(API’s), human health and animal health.

ABOUT NUCELIS AND CIBUS

Cibus is a biotechnology company using advanced technologies to develop
desirable plant traits for the global seed industry by precisely editing
a plant’s genes without the integration of foreign genetic material.
This technique accelerates natural breeding that has been a staple of
farming for thousands of years and has been classified in certain key
agricultural markets as not subject to GMO regulation. Cibus has
launched its first commercial canola product, Falco™, and is developing
a pipeline of beneficial traits in other crops that it plans to license,
including healthier oil quality, disease resistance, and herbicide
tolerance. Cibus has established crop platforms in canola, rice, flax,
potato, and is now developing platforms in wheat, corn, soybean and
peanut. The broad applicability of Cibus’ technologies is highlighted by
Nucelis, which extends the company’s trait development program to
microorganisms, including yeast, bacteria and algae, for the food,
flavor and fragrance and personal care markets. The company has
subsidiaries in Europe and North America and a state-of-the-art research
and development center in San Diego.

Contacts

Jim Mazzola
jmazzola@cibus.com
858-450-2612

Karen Troeber
ktroeber@cibus.com
858-450-2636

Source: Cibus


Voir aussi

Maverick Therapeutics to Unveil Pre-Clinical Data on Novel COBRATM Platform at American Association for Cancer Research 2019 Annual Meeting

Saturday, March 30th 2019 at 12:00pm UTC – Pre-clinical Data Characterize the Conditional and Potent …